Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study by Nichols, B.E. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/118224
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in
Preventing HIV-1 Infections in Rural Zambia: A Modeling
Study
Brooke E. Nichols1*, Charles A. B. Boucher1, Janneke H. van Dijk2, Phil E. Thuma2, Jan L. Nouwen1,
Rob Baltussen3, Janneke van de Wijgert4, Peter M. A. Sloot5, David A. M. C. van de Vijver1*
1Department of Virology, Erasmus Medical Centre, Rotterdam, The Netherlands, 2Macha Mission Hospital and Macha Research Trust, Macha, Zambia, 3Department of
Primary and Community Care, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, 4 Institute of Infection and Global Health, University of
Liverpool, Liverpool, United Kingdom, 5Computational Science, Faculty of Science University of Amsterdam, Amsterdam, The Netherlands
Abstract
Background: Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine effectively prevents new HIV infections. The
optimal scenario for implementing PrEP where most infections are averted at the lowest cost is unknown. We determined
the impact of different PrEP strategies on averting new infections, prevalence, drug resistance and cost-effectiveness in
Macha, a rural setting in Zambia.
Methods: A deterministic mathematical model of HIV transmission was constructed using data from the Macha epidemic
(antenatal prevalence 7.7%). Antiretroviral therapy is started at CD4,350 cells/mm3. We compared the number of infections
averted, cost-effectiveness, and potential emergence of drug resistance of two ends of the prioritization spectrum:
prioritizing PrEP to half of the most sexually active individuals (5–15% of the total population), versus randomly putting 40–
60% of the total population on PrEP.
Results: Prioritizing PrEP to individuals with the highest sexual activity resulted in more infections averted than a non-
prioritized strategy over ten years (31% and 23% reduction in new infections respectively), and also a lower HIV prevalence
after ten years (5.7%, 6.4% respectively). The strategy was very cost-effective at $323 per quality adjusted life year gained
and appeared to be both less costly and more effective than the non-prioritized strategy. The prevalence of drug resistance
due to PrEP was as high as 11.6% when all assumed breakthrough infections resulted in resistance, and as low as 1.3% when
10% of breakthrough infections resulted in resistance in both our prioritized and non-prioritized scenarios.
Conclusions: Even in settings with low test rates and treatment retention, the use of PrEP can still be a useful strategy in
averting infections. Our model has shown that PrEP is a cost-effective strategy for reducing HIV incidence, even when
adherence is suboptimal and prioritization is imperfect.
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Introduction
Despite extensive prevention efforts there were 2.6 million new
HIV infections in 2009 globally [1]. While the annual number of
new infections has been decreasing since 1997, there is still an
urgent need for more effective prevention strategies in addition to
use of condoms and behavior change. Pre-exposure prophylaxis
(PrEP) with daily oral tenofovir and emtricitabine has been shown
to be efficacious in preventing HIV infections [2,3,4]. In the recent
Partner’s PrEP study among African heterosexual serodiscordant
couples, daily PrEP was shown to prevent 73% of infections over
three years of follow-up compared to the control arm [3].
Similarly, the TDF-2 trial among heterosexual men and women in
Botswana showed that daily PrEP prevented 62% of infections
over a median of 1.1 years compared to the control arm [4]. In the
recent iPrEx study, daily PrEP was shown to prevent 44% of
infections over a median of 1.2 years compared to the control arm
in a highly sexually active cohort of men who have sex with men
(MSM) [2]. The FEM-PrEP trial, among heterosexual African
women did not, however, find a protective effect of PrEP, likely
due to poor adherence [5].
It is unknown who should receive PrEP so that most infections
are averted at the lowest cost. The cost-effectiveness of PrEP has
not been established for a low-income country such as Zambia.
Two hypothetical PrEP distribution scenarios could be utilized.
First, PrEP could be given to more sexually active individuals,
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Table 1. Model Parameters.
Description Estimate or Range* Reference
Test rate 10–20% Macha, Zambia
Rate of being tested in the acute stage of HIV 50% of the test rate Assumption**
Rate of being tested in the chronic stage of HIV test rate Macha, Zambia
Rate of being tested in the AIDS stage test rate +10% Macha, Zambia
Disease stages duration [10,11,12,13]
Acute stage 10–16 weeks
Chronic stage 8.31–8.43 years
AIDS stage 6–12 months
Final AIDS stage 7–13 months
Proportion of people in sexual risk groups Model Calibration
Highest*** 1.0%–2.9%
2nd*** 15.1%–24.0%
3rd 10%
Lowest 63.1%–73.9%
Number of partners per year in each sexual risk group Model Calibration
Highest*** 7–31
2nd*** 1.5–2.6
3rd 0.1
Lowest 0.03
Mortality rates per year [39]
Population 0.02
Chronic HIV stage 0.098
AIDS stage 0.63
On treatment during chronic stage, first 3 months 0.05–0.098
On treatment during chronic stage, second 3 months 0.03–0.06
On treatment during chronic stage, 6+ month 0.02–0.05
On treatment during AIDS stage, first 3 months 0.1–0.3
On treatment during AIDS stage, second 3 months 0.05–0.12
On treatment during AIDS stage, 6+ month 0.03–0.06
Linkage to care from test to treat 70% Macha, Zambia
Proportion of people on PrEP
Non-prioritized PrEP 40–60%{ Assumption
Prioritized PrEP (approximately half of highest two sexual risk groups) 5–15%{ Assumption
Effectiveness of PrEP [2,3,4]
Moderate Adherence 20–60%
High Adherence 50–90%
Reduction in transmissibility of those patients on treatment 90–100% [25,26,27]
Rate of resistance among those infected despite use of PrEP 10%, 50%, 100% Assumption
Rate of discontinuation of PrEP (not due to resistance) 4–5% [40]
Number of HIV tests per year on PrEP 1–4 Assumption
Number of HIV clinic visits in first year 8 Macha, Zambia
Number of yearly HIV clinic visits after first year 4 Macha, Zambia
Costs
Cost of PrEP per year (TDF/FTC) (1) $126 ($137.12) [28,29]
Cost of testing negative for HIV per test (1) $1 ($3.78) Macha, Zambia, [28]
Cost of testing positive for HIV per test (1) $3.84 ($9.4) Macha, Zambia, [28]
Cost of an inpatient day in the hospital $10.27 [28]
Cost of an outpatient visit in the hospital $2.78 [28]
Cost of treatment per year (TDF/FTC+EFV) (1) $194 ($243) [29]
Cost of a CD4 Count test (1) $31–$39
($34–$42)
Macha, Zambia, [28]
Cost-Effectiveness of PrEP, Zambia
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potentially by identifying a seronegative partner in a serodiscor-
dant relationship or people with sexually transmitted infections
(STIs) and their partners. Another hypothetical approach could be
to randomly assign PrEP to individuals regardless of level of sexual
activity in order to avert infections.
The drugs used in PrEP regimens are the same as those
recommended for first-line treatment regimens. A critical issue in
PrEP use is therefore the development of HIV drug resistance in
the population. Potential risks associated with using the same drugs
for both prevention and for treatment can be illustrated by the use
of nevirapine for prevention of mother-to-child transmission [6].
Recent maternal use of nevirapine for prevention of mother-to-
child-transmission was associated with a higher probability of
virological failure in the mothers receiving nevirapine as part of
their first-line regimen [7].
Our objective is to use mathematical modeling to explore the
possibilities of daily oral PrEP optimization using realistic data
collected in the rural HIV clinic at the Macha Mission Hospital in
Zambia. Rural settings such as Macha often face more barriers to
treatment, such as large travel distances to clinics and fewer
financial resources available [8]. Particularly in these settings,
optimized PrEP strategies can be of great additional value from
both a public health and economic perspective. We therefore
evaluated the impact of hypothetical scenarios in which PrEP is
prioritized to individuals with the highest sexual activity or is
distributed randomly. We could therefore determine cost-effec-
tiveness at both ends of the PrEP distribution spectrum, from
where PrEP is given to those at highest risk of becoming infected,
to giving PrEP to individuals regardless of risk. We additionally
aimed to evaluate the risk for resistance development.
Methods
Setting and Population
Our model is based on the rural population of Macha, Zambia
and using data from the HIV Clinic at Macha Hospital. Macha is
located in the Southern Province of Zambia, and approximately
80 km away from the nearest town, Choma [8]. The hospital
serves as a district-level referral hospital for rural health centers
within an 80 km radius, with 90,000 persons that are aged 12
years and over in the Macha Hospital catchment area [8]. The
antenatal prevalence between 2002 [9] and 2009 [local data] was
stable around 7.7%. Macha Hospital has provided care to over
7500 HIV-infected adults and children since 2005 through the
Government of Zambia’s antiretroviral treatment program, with
additional support from the President’s Emergency Plan for AIDS
Relief (PEPFAR) through the non-governmental organization,
AidsRelief [8]. Since the start of the clinic in 2005, treatment is
implemented according to WHO guidelines, initially at CD4,200
cells/mm3, and at CD4,350 cells/mm3 since 2010. The HIV
pharmacy is well-stocked and treatment is readily available for all
diagnosed patients who drop below the treatment threshold.
Model and Assumptions
A compartmental deterministic mathematical model was
constructed and parameters were chosen to represent the
Macha setting (Table 1). Our model stratifies disease progres-
sion into an acute stage, a chronic stage and two AIDS stages
(Figure S1). Two AIDS stages are included because during the
final months before death, patients will have limited sexual
activity and are therefore assumed not to transmit HIV [10,11].
The acute stage has a duration that ranged between 10 and 16
weeks [12]. The combined duration of the acute stage and the
chronic stage is 8.5–8.7 years [10,13]. The pre-final AIDS stage
ranged between 6 and 12 months [10,11]. Compared to the
chronic stage, it was assumed that infectivity was 27–43 times
higher in the acute stage [14] and 3–5 times higher in the
AIDS stage [10,11] (Table 1).
Individuals that test positive for HIV can reduce their risk
behavior [15,16,17], largely due to a reduction in acquisition of
new partners [15]. Based on recent work done in neighboring
Zimbabwe, it is assumed in our model that patients will reduce
the acquisition of new partners by 0–40% [18].
Model Description and Validation. Following earlier
model’s methods for defining risk structure [19,20], the model
identifies four sexual activity groups ranging in the number of
new sexual partners per year [21]. Data about the proportion of
individuals in a particular sexual activity group and their
number of new partners are not available. Using the Monte
Carlo filtering techniques [22] we parameterized the different
sexual activity groups and only accepted the 1795 simulations
that were associated with a prevalence of 7.7% (60.05%) from
2002 until 2009 in accordance with Macha. Monte Carlo
filtering allowed us to test the impact of PrEP over a wide
range of sexual activities, as a wide variety of sexual risk group
combinations resulted in the appropriate HIV prevalence
(Table 1).
In summary, the highest sexual activity group had an average of
13 new partners per year and made up on average just 2% of the
population, representing a core group of highly sexually active
individuals. This group is instrumental in determining the peak of
the epidemic. Only simulations where this group was small and
their number of partners were high allowed the epidemic to peak
appropriately. The second highest sexual activity group had on
average 2 new partners per year and made up a more substantial
18% of the population, representing individuals whom are not in
steady or monogamous relationships. This is the group is an
important factor in determining where the equilibrium of the
Table 1. Cont.
Description Estimate or Range* Reference
Cost discounting rate per year 3%
Exchange rate, Zambian Kwacha to USD over year 2011 3845:1
*All ranges are uniformly distributed, except where indicated.
**Due to window phase of antibody-based test.
***Not uniformly distributed, see figure S2.
{Not uniformly distributed, median 43% over 10 years;
{Not uniformly distributed, median 12% over 10 years;
1Comprehensive costs, including costs of outpatient visits, additional laboratory tests, laboratory personnel.
doi:10.1371/journal.pone.0059549.t001
Cost-Effectiveness of PrEP, Zambia
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epidemic is reached. The only simulations that were accepted into
the analysis were the ones in which this group allowed the
epidemic to reach an equilibrium prevalence of 7.7% (60.05%)
from 2002–2009 in accordance with Macha data. The two lowest
groups had ,1 new sexual partner per year, representing
individuals in long term relationships or marriages. The final
distribution of proportion of sexual activity groups and number of
new partners per year are given in Figure S2. Other variables used
to calibrate the model included: transmissibility during the acute
stage of infection, transmissibility during the AIDS stage of
infection, the rate at which individuals moved from acute to
chronic infection, rate at which individuals move from the AIDS
stage to the AIDS final stage, and the rate of mixing between
sexual risk groups (epsilon). Full model description including
equations can be found in the Text S1.
HIV testing. Approximately 10% of individuals aged 12 and
older undergo an HIV-test yearly in Macha. In our model, we
studied the impact on the HIV-epidemic of test rates that were
ranged randomly between the current level and a double
proportion of 20% [23]. We assumed different test rates for
different stages of disease progression (Table 1).
Treatment. After a positive HIV-test, 70% of individuals are
retained in care. Treatment is then started at CD4,350 cells/
mm3. In the AIDS stage, there is therefore immediate treatment
after diagnosis. Additionally it takes approximately 4 years to
progress from infection to CD4,350 cells/mm3 [24]. Treatment
reduces the infectivity by 90–100% as compared to the chronic
stage [25,26,27].
Scenario Assumptions
Baseline. Our baseline in this model is the current practice in
Macha (i.e. test rate 10–20%, retention 70% and start of treatment
at CD4,350 cells/mm3).
Non-Prioritized versus Prioritized PrEP
distribution. We examined the impact of two hypothetical
scenarios where PrEP is perfectly and imperfectly prioritized to
represent both ends of the prioritization spectrum. In the first
hypothetical scenario, we examined the impact of completely
perfect prioritization by assigning approximately half of the
individuals in the two highest sexual activity groups, 5–15% of
the population (4,500–13,500 individuals), to receive PrEP. We
assigned just half of the highest sexual activity groups, as
identifying those groups completely would likely not be feasible.
In the second hypothetical scenario where PrEP is imperfectly
prioritized, PrEP is assigned to half of the population in a non-
prioritized manner by assigning PrEP to 40–60% of the
population at random (36,000–54,000 individuals). Time to reach
PrEP coverage was 1–2 years.
PrEP adherence. Adherence is key in PrEP use as illustrated
by all recent PrEP studies [2,3,4,5]. Since it is unknown what level
of adherence would be expected in Macha, we examined a high
population-level adherence scenario and ranged PrEP effective-
ness from 50%–90%, derived from the highly adherent in recent
PrEP trials [2,3,4], and a moderate population-level PrEP
adherence scenario, where effectiveness ranged from 20%–60%.
Drug resistance. Rates of drug resistance due to PrEP are
currently unknown. Drug resistance may emerge in individuals
who become infected with HIV despite the use of PrEP. It is
unknown how rapidly resistance will emerge after PrEP failure.
We therefore evaluated a scenario with low resistance develop-
ment, where resistance develops in 10% of breakthrough infections
(infections despite the use of PrEP). We also evaluated a moderate
resistance and high resistance scenario, where resistance emerges
in 50% and 100% of breakthrough infections respectively. The
prevalence of drug resistance is expressed as the proportion of
individuals with a resistant virus over the total number of
infections in the population.
Cost-effectiveness Analysis
In order to evaluate the feasibility of the range in PrEP
implementations, we conducted a cost-effectiveness analysis. Each
compartment in our deterministic model was assigned a range of
cost and quality adjusted life year (QALY) depending on the
intervention (Table 1, and Tables S1, S2, S3). A QALY of 1 means
one year of life lived in perfect health. As our base, a susceptible
person not on PrEP was considered to have no reduction in
health-related quality of life. Rates of HIV clinical tests were taken
from Macha’s standard practice, including the different types of
tests and how frequently they are administered. Costs and rates for
hospitalization of HIV infected persons, opportunistic infections
(Table S4), HIV testing, and treatment, were all taken into
account using costs from Macha and the WHO-CHOICE costing
database [28]. Current ARV costs were taken from the 2011
Clinton Health Access Initiative negotiated prices [29]. An
intervention is said to be cost-effective if it costs less than three
times the gross national income (GNI) per capita ($3210 in
Zambia [30]) per QALY gained. An intervention is defined as very
cost-effective at a cost up to one times the GNI per capital ($1070
in Zambia [30]) per QALY [31,32]. We calculated both the
average cost-effectiveness ratios where we compared each scenario
to baseline, and the incremental cost-effectiveness ratios where we
compared each scenario to the next least-costly scenario [33]. We
follow methodological guidelines on cost-effectiveness analysis
[33], and only consider the latter as meaningful for making
optimal resource allocation decisions. All costs have been
discounted yearly (converting future costs into present terms) at
the standard of 3%.
Sensitivity Analysis
We performed one-way deterministic sensitivity analysis of cost-
effectiveness where our baseline model for comparison was the
prioritized PrEP model with moderate PrEP adherence. Eight key
input variables, HIV prevalence, PrEP efficacy, proportion of
people in highest two sexual activity groups on PrEP, number of
HIV tests per year for those on PrEP, cost of antiretroviral drugs,
total costs depending on the exchange rate, cost and QALY
discounting were considered to identify the sensitivity of our
model. We also determined the amount of additional money that
could be spent on infrastructure and programmatic costs of
implementing prioritized PrEP and have the intervention still be
(very) cost-effective.
Ethics Statement
Written informed consent was obtained from the study
participants. Ethical approval was granted by the University of
Zambia Biomedical Research Ethical Committee in 2008 before
data collection began.
Results
Baseline Scenario: Start of Treatment at CD4,350 Cells/
mm3
The impact of treatment alone under the current guidelines of
treatment at CD4,350 cells/mm3 reduces incidence, showing an
18% decline in new infections over 10 years. The prevalence
remained stable at 7.7% after 10 years, as treatment dramatically
reduces mortality and patients therefore remain alive.
Cost-Effectiveness of PrEP, Zambia
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Prioritized Versus Non-Prioritized PrEP
Compared to our baseline scenario of starting treatment at
CD4,350 cells/mm3, prioritizing PrEP will result in 3200
infections averted over 10 years (31% reduction; interquartile
range (IQR) 23%–39%), whereas a non-prioritized PrEP strategy
will result in just 2333 infections averted (23% reduction; IQR:
16–30%) (Figure 1A, 1E). The prevalence in the prioritized
approach is lower after 10 years, at 5.7% (IQR: 5.2%–6.2%),
compared to a prevalence of 6.4% (IQR: 6.0%–6.7%) in the non-
prioritized strategy (Figure 1B, 1F).
Impact of Adherence
As expected, high PrEP adherence had a strong impact on the
HIV epidemic as compared to moderate PrEP adherence in both
the prioritized and non-prioritized strategies. The impact,
however, was stronger than expected. In the non-prioritized
strategy, compared to baseline, an estimated 4333 infections (42%
reduction; IQR: 35%–50%) were averted with high adherence to
PrEP (Figure 1C), 2000 more than with moderate adherence. In
the prioritized strategy, compared to baseline, an estimated 5697
infections (56% reduction; IQR: 47%–64%) were averted with
high adherence to PrEP (Figure 1G), almost 2500 more than with
moderate adherence. High adherence also has a strong impact on
the HIV prevalence after 10 years of the intervention, with a
median prevalence of 5.1% (IQR: 4.7%–5.5%) in the non-
prioritized strategy and 4.2% (IQR: 3.6%–4.7%) in the prioritized
strategy (Figure 1D, 1H).
Figure 1. Prioritizing highest sexual risk groups versus a non-prioritized PrEP strategy, incidence and prevalence.
doi:10.1371/journal.pone.0059549.g001
Figure 2. Prevalence of drug resistance due to PrEP over 10 years.
doi:10.1371/journal.pone.0059549.g002
Cost-Effectiveness of PrEP, Zambia
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Drug Resistance and PrEP
Investigating the impact of PrEP on resistance development
showed that when 100% of breakthrough infections developed a
drug resistant virus with moderate adherence, the prevalence of
drug resistance due to PrEP was strikingly high. In the prioritized
PrEP scenario, there was an 11.6% (IQR 10.3%–12.8%)
prevalence of drug resistance due to PrEP alone after 10 years
(Figure 2). Assuming a 50% and 10% drug resistance rate among
PrEP users resulted in a 6.1% (IQR 5.3%–6.8%) and 1.3% (IQR
1.1%–1.4%) drug resistance prevalence due to PrEP after 10
years. The results were almost identical in our non-prioritized
scenario.
Adherence, however, appears to strongly impact the prevalence
of drug resistance due to PrEP. With high adherence, the drug
resistance due to PrEP was 7.1% (IQR 5.3%–8.8%) in the
prioritized scenario, approximately 4% lower than in the
moderate adherence scenario, assuming a 100% drug resistance
rate among PrEP users. Assuming a 50% and 10% drug resistance
rate among PrEP users resulted in a 3.7% (IQR 2.6%–4.6%) and
0.8% (IQR 0.5%–1.0%) drug resistance prevalence due to PrEP
after 10 years in the prioritized scenario. The results were again
almost identical in our non-prioritized scenario with high
adherence.
Cost-effectiveness
We evaluated the cost-effectiveness of the prioritized and non-
prioritized PrEP interventions compared with the baseline
(Table 2). Our baseline scenario cost $4.3 million (IQR: $3.8–
$4.7 million) over 10 years. Of that amount, approximately 54%
would be covered under PEPFAR as long as PEPFAR continues.
A total of 10222 infections would be expected over 10 years.
The prioritized PrEP strategy cost an additional $11.5 million
(IQR: $11.1–$13.4 million) compared to the baseline strategy. A
median of 36,216 QALYs would be gained (IQR: 26,174, 45,690)
with the prioritized scenario over 10 years.
The non-prioritized PrEP strategy cost an additional $43.9
million (IQR: $41.4, $46.0 million) compared to baseline. A
median of 23,571 QALYs would be gained (IQR: 15,680, 31,764)
with the non-prioritized scenario over 10 years.
Based on the interpretation of average cost-effectiveness ratios
only, both strategies can be considered (very) cost-effective.
However, the interpretation of incremental costs and effects of
the prioritized PrEP strategy as compared to the non-prioritized
strategy reveals that the former strategy is both less costly and
more effective, and ‘dominates’ the latter. This means that the
non-prioritized PrEP strategy cannot be considered economically
attractive. The incremental cost-effectiveness ratio of the priori-
tized PrEP strategy is $323 per QALY (IQR: $257, $428) and this
strategy can thus be considered very cost-effective.
Sensitivity Analysis
One-way sensitivity analyses (Figure 3) highlighted the eight key
input parameters of our model. Even when just 10% of the highest
two sexual activity groups are prioritized for PrEP (2% of the total
population, or 1,800 individuals), the cost per QALY is actually
lower than when approximately half of the two highest sexual
activity groups are prioritized, at only $177 per QALY. This
shows that targeting just a small fraction of those individuals in a
higher sexual activity group would be optimal from a cost-
effectiveness perspective.
It appears that PrEP will be more cost-effective in regions with
higher HIV prevalence at $161 per QALY in a region with a
prevalence of 15%. In contrast, prioritized PrEP is no longer very
cost-effective for a prevalence of 1%, at $2062 per QALY. The
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remainder of the parameters–frequency of HIV testing on PrEP,
PrEP effectiveness (as controlled by adherence [2]), cost of ARVs,
cost and QALY discounting rate, and exchange rate– did not
result in large differences in cost-effectiveness from our baseline
prioritized model.
If implemented, the prioritized PrEP strategy could spend an
additional $25.2 million over 10 years on infrastructure and
programmatic costs and remain very cost-effective ($94.8 million
to remain cost-effective) (Table 2).
Discussion
Our model has shown that PrEP is a cost-effective strategy for
reducing HIV incidence, even when prioritized imperfectly and
distributed regardless of risk of acquiring HIV. If PrEP can be
perfectly prioritized to the most sexually active individuals, it is a
very cost-effective prevention method and averts 31% of infections
averted over 10 years at $323 per QALY. Even when prioritizing
just a small fraction of the highly sexually active, PrEP is very cost-
effective at $177 per QALY gained.
The prevalence of drug resistance due to PrEP could be high. It
is therefore important to closely monitor patients who become
infected despite the use of PrEP for resistance. Drug resistance is,
however, much lower when adherence to PrEP is higher.
A strength of our study is access to cost and epidemiologic data
from Macha, a rural setting in Zambia. Access to this dataset
enables us to make reliable predictions about the potential
implementation of PrEP. Another strength is that there is limited
migration into and out of Macha as transportation and mobility
are limited. Migration can have a major impact on a local HIV
epidemic, and also on a mathematical model attempting to
capture HIV dynamics in a population. The population in Macha
has, however, remained fairly stable over time.
A limitation of our modeling approach is that highly sexually
active individuals are difficult to identify. Nonetheless, we found
that cost-effectiveness remained the same if only 10% of the high
sexual activity groups could be prioritized (2% of the total
population). Health care providers could begin with prioritizing
those individuals who present with STI symptoms at clinics, or are
identified as the seronegative partner in a serodiscordant
relationship. Over a wide spectrum of adherence and PrEP
prioritization, we predict that PrEP will reduce HIV incidence and
will be cost-effective.
Our model does not take into account administrative program
costs [34], as they would vary widely depending on the precise
intervention used. We have also not included indirect costs, as
these are very difficult to quantify. We have instead shown the
additional amount that could be spent on those costs and retain
cost-effectiveness. The government of Zambia or donors could
invest an additional $25,200,000 over 10 years in the implemen-
tation of prioritized PrEP, and have it remain very cost-effective.
Previous models have shown the potential impact of PrEP. A
model by Pretorius et al. evaluated cost-effectiveness in a
generalized South African epidemic [35]. When all individuals
were assigned to receive PrEP, they showed a decrease in
incidence in 2025 of about 40% compared to their baseline. This
is approximately in line with our findings, albeit a bit low
considering that we assigned PrEP to half of our population.
A model by Abbas et al. investigated the factors influencing the
emergence and spread of HIV drug resistance arising from PrEP
rollout, based on a general mature epidemic in sub-Saharan Africa
[36]. In their PrEP scenario analyses, the largest decrease in
infections was achieved with a non-prioritized strategy (31% in an
optimistic scenario, similar to our ‘‘high adherence’’ scenario; 7%
in realistic, similar to our ‘‘moderate adherence’’) and the smallest
decrease with the prioritized-by-activity strategy (8% in optimistic,
3% in realistic). The benefits of PrEP in this model were much
lower than estimates from our model. Reasons for this could be
their definitions of optimistic and realistic, as well as the level of
protection offered from PrEP.
In iPrEx, HIV drug resistance due to PrEP was not a major
issue [2], likely due to monthly monitoring of participants for
seroconversion. The only resistance found was in those with a false
negative HIV test at randomization and started PrEP. The study
by Abbas et al. has also examined the emergence of drug resistance
due to PrEP in a heterosexual sub-Saharan epidemic [36]. In
agreement with our results, the Abbas model has shown that there
is not much difference in the prevalence of drug resistance in a
Figure 3. One-way sensitivity analyses of the incremental cost-effectiveness of PrEP.
doi:10.1371/journal.pone.0059549.g003
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non-prioritized or prioritized PrEP scenario, but that higher PrEP
adherence would result in less drug resistance. The total
prevalence of resistance in their optimistic scenario was about
1.9–2.5% and 9.2–9.9% in their realistic scenario. If we had
evaluated the same measure of drug resistance, these figures are
likely lower than ours.
Several prevention strategies using antiretroviral drugs have
been shown to be effective in reducing new infections with HIV.
These strategies include antiretrovirals for prevention of mother-
to-child transmission [7,37], topical tenofovir as an intra-vaginally
applied microbicide [38] and earlier start of treatment as
prevention [27]. Our baseline model looks at the impact of
starting treatment at a CD4 count of ,350 cells/mm3, and found
that starting treatment at that cutoff is already an intervention.
Incidence was reduced by more than 30% after 10 years.
iPrEx is the first study to be published looking at the efficacy of
PrEP, and was investigating an MSM community with high
numbers of sexual contacts. Results on the effectiveness of PrEP in
heterosexuals have also been reported [3,4,5]. FEM-PrEP trial had
enrolled 1,951 African women to investigate the efficacy of TDF/
FTC as PrEP, and was recently discontinued due to lack of an
effect, likely due to adherence [5]. Two studies, however, found
more encouraging results. The Partner’s PrEP study of 4,758
serodiscordant couples based in Kenya and Uganda found a 73%
reduction in risk of the participants on TDF/FTC compared to
placebo [3]. Similarly, the CDC’s Botswana-based TDF2 study
found a 63% reduction in risk of those assigned to receive daily
PrEP [4]. Adherence to PrEP is key as the highly adherent in both
iPrEx and Partner’s PrEP appeared to have the same level of high
PrEP efficacy, showing that PrEP works similarly irrespective of
MSM or heterosexual transmission.
Even in settings with low test rates and treatment retention, the
use of PrEP can still be a useful strategy in averting infections. Our
model has shown that PrEP is a cost-effective strategy for reducing
HIV incidence, even when adherence is suboptimal and priori-
tization is imperfect. Particularly in high prevalence settings,
prioritizing PrEP to high sexual activity groups could be a cost-
effective way to curb the epidemic. Effective ways to prioritize high
sexual activity groups in a heterosexual epidemic and maximize
adherence should be investigated further in order to increase the
numbers of infections averted and cost-effectiveness.
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